Palvella Therapeutics, Inc. Fair Value Adjustment of Warrants
Palvella Therapeutics, Inc. (PVLA) reported Fair Value Adjustment of Warrants of $0 for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-23.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2016-03-23
- Palvella Therapeutics, Inc. fair value adjustment of warrants for fiscal 2015 was $0.00, a 100.00% decline from fiscal 2014.
- Palvella Therapeutics, Inc. fair value adjustment of warrants for fiscal 2014 was $700.00K.
| Period end | Fair Value Adjustment of Warrants 12 month | Fair Value Adjustment of Warrants 12 month as first filed |
|---|---|---|
| 2015-12-31 | $0.00 10-K · filed 2016-03-23 | |
| 2014-12-31 | $700.00K 10-K · filed 2016-03-23 | $664.06K 10-K · filed 2015-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |